Skip to main content

Table 1 Demographic, clinical, and biohumoral characteristics at baseline of the 70 AS patients who were treated with infliximab treatment and classified into two groups: those still taking the drug (responders) or not taking the drug (non-responders) at the end of the five year period

From: Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab

  Responders Non-responders p*
N 35 35  
Male, N (%) M 29 (82.9 %) M 23 (65.7 %) ns
Age (years) 50.3 ± 12.5 48.5 ± 11.0 ns
DiseaseDuration (years) 17.9 ± 10.6 16.3 ± 9.3 ns
MTX intake, N (%) 15 (42.9 %) 12 (34.3 %) ns
Sulfasalazine, N (%) 3 (8.6 %) 5 (14.3 %) ns
Prednisone intake, N (%) 5 (14.3 %) 14 (40 %) <0.005*
Uveitis, N (%) 1 (4.1 %) 1 (4.1 %) ns
IBD, N (%) 1 (4.1 %) 0 ns
NSAIDS, N (%) 29 (82.9 %) 27 (77.1 %) ns
ESR (mm/H) 21.5 ± 18.3 31.0 ± 25.1 ns
CRP (mg/dL) 1.9 ± 1.6 1.7 ± 1.5 ns
BASDAI 59.5 ± 15.3 59.9 ± 19.6 ns
BASFI 47.1 ± 16.8 52.2 ± 25.1 ns
BASMI 5.9 ± 1.3 5.4 ± 1.6 ns
VAS 64.9 ± 16.9 62.9 ± 18.8 ns
VASg 50.5 ± 21.4 61.1 ± 19.0 0.05*
  1. N number, MTX Methotrexate, IBD Inflammatory Bowel Diseases, NSAIDs Non Steroidal Anti-Inflammatory Drugs, ESR Erytrocyte Sedimentation Rate, CRP C-Reactive Protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondilitis Metrology Index, VAS Visual Analogue Scale pain, VASg Visual Analogue Scale global disease activity
  2. Data expressed as mean ± standard deviation, unless otherwise indicated
  3. *Mann Whitney test